樂普生物-B(02157.HK)首次實現盈利 預計上半年利潤不少於2400萬元
格隆匯8月6日丨樂普生物-B(02157.HK)公佈,截至2025年6月30日止六個月,預計公司將錄得利潤不少於人民幣2,400萬元,而截至2024年6月30日止六個月的上年同期則虧損約人民幣1.97億元。這是公司首次實現盈利。
公司於報告期轉虧爲盈主要得益於收入的大幅成長,其中主要包括與ArriVent BioPharma, Inc.就MRG007開展的許可合作收入,以及普佑恆?(普特利單抗注射液)的銷售收入增長。有關上述許可安排的詳情,請參閱本公司日期爲2025年1月22日的公告。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.